10 July 2014Americas

Pfizer facing three Celebrex antitrust cases

Pfizer is facing three class actions that allege the pharmaceutical company improperly obtained a patent covering its arthritis drug Celebrex (celecoxib) and used it to force generic drug makers into settlements that delay their entry into the market, Law360 has reported.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
3 February 2026   Nominations are open for the Life Sciences Patent Network's 2026 awards in Boston, including six new categories and winners selected by leading industry experts.
Americas
29 January 2026   A judge has allowed antitrust claims against the pharma giant to move forward, finding that it plausibly used bundled rebates and patent abuse to extend its insulin monopoly, though one allegation was dismissed.
Americas
28 January 2026   The rise of fake online stores selling counterfeit pharmaceuticals is driving a surge in domain name disputes, forcing major brands to defend revenue and reputation.